New RA pill takes on tofacitinib in Head-to-Head trial
NCT ID NCT06020144
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a new oral drug called TLL-018 works better than tofacitinib for active rheumatoid arthritis. The study includes 459 adults aged 18-65 who have not responded well to or cannot tolerate biologic treatments. Participants take either TLL-018 or tofacitinib for 52 weeks, and researchers measure joint pain, swelling, and disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TLL-018 (oral tablet)
What this could lead to
If successful, TLL-018 could offer a new oral treatment option for people with rheumatoid arthritis who have not responded well to biologic drugs.
What could go wrong
This is a head-to-head comparison against an existing drug, so TLL-018 may not prove superior. As with any RA treatment, there are risks of infection and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China